Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Corvatta

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
European Journal of Haematology|February 9, 2007
Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myelomaMassimo Offidani, Sara Bringhen, Laura Corvatta, et al.
Haematologica|March 9, 2004
Mucormycosis in hematologic patientsLivio Pagano, Massimo Offidani, Luana Fianchi, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|August 7, 2004
Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myelomaMassimo Offidani, Laura Corvatta, Monica Marconi, et al.
European Journal of Haematology|May 7, 2004
Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathyMassimo Offidani, Laura Corvatta, Monica Marconi, et al.
Annals of Hematology|March 26, 2011
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myelomaMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Leukemia & Lymphoma|February 17, 2012
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myelomaMassimo Offidani, Claudia Polloni, Federica Cavallo, et al.
British Journal of Haematology|January 20, 2007
Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scansAnna Mele, Massimo Offidani, Giuseppe Visani, et al.
Clinical Lymphoma & Myeloma|October 16, 2008
Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapyMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Leukemia & Lymphoma|May 26, 2010
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match studyMassimo Offidani, Pietro Leoni, Sara Bringhen, et al.
European Journal of Haematology|March 25, 2010
ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myelomaMassimo Offidani, Pietro Leoni, Laura Corvatta, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
European Journal of Haematology|February 9, 2007
Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myelomaMassimo Offidani, Sara Bringhen, Laura Corvatta, et al.
Haematologica|March 9, 2004
Mucormycosis in hematologic patientsLivio Pagano, Massimo Offidani, Luana Fianchi, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|August 7, 2004
Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myelomaMassimo Offidani, Laura Corvatta, Monica Marconi, et al.
European Journal of Haematology|May 7, 2004
Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathyMassimo Offidani, Laura Corvatta, Monica Marconi, et al.
Annals of Hematology|March 26, 2011
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myelomaMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Leukemia & Lymphoma|February 17, 2012
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myelomaMassimo Offidani, Claudia Polloni, Federica Cavallo, et al.
British Journal of Haematology|January 20, 2007
Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scansAnna Mele, Massimo Offidani, Giuseppe Visani, et al.
Clinical Lymphoma & Myeloma|October 16, 2008
Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapyMassimo Offidani, Laura Corvatta, Claudia Polloni, et al.
Leukemia & Lymphoma|May 26, 2010
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match studyMassimo Offidani, Pietro Leoni, Sara Bringhen, et al.
European Journal of Haematology|March 25, 2010
ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myelomaMassimo Offidani, Pietro Leoni, Laura Corvatta, et al.
Pageof 5